Aptus Pharma Ltd

Shares of Aptus Pharma surged 23.89% in ten trading sessions from its recent closing low of Rs 169.50 on 31 December 2025. The stock hit an all-time high of Rs 210 today. On the BSE, 0.36 lakh shares have been traded so far, compared with an average daily volume of 0.50 lakh shares over the past two weeks. The stock had outperformed the market over the past month, rising 29.63% as against the Sensex's 0.88% drop. The stock had outperformed the market over the three months, rising 137.77% as against the Sensex's 3.15% jump. On the technical front, the stock's daily RSI (relative strength index) stood at 83.352. The RSI oscillates between zero and 100. Traditionally, the RSI is considered overbought when above 70 and oversold when below 30. On the daily chart, the stock was trading above its 50-day, 100-day, and 200-day simple moving average (SMA), placed at 80.80, 77.33, and 42.35, respectively. These levels will act as crucial support zones in the near term. Aptus Pharma is engaged in the business of marketing and distribution of finished pharmaceutical formulations. The company's consolidated net profit surged 270% to Rs 2.96 crore on a 37.5% jump in net sales to Rs 24.56 crore in FY26 over FY25.Powered by Capital Market - Live

Aptus Pharma will hold a meeting of the Board of Directors of the Company on 10 November 2025.Powered by Capital Market - Live

The scrip was listed at Rs 80.80, a premium of 15.43% over the initial public offer (IPO) price. The stock is currently up 3.96% over its listing price. The counter hit a high of Rs 84.84 and a low of Rs 80.80. About 8.18 lakh shares of the company changed hands at the counter. Aptus Pharma's IPO was subscribed 20.79 times. The issue opened for bidding on 23 September 2025 and it closed on 25 September 2025. The price band of the IPO was fixed between Rs 65 to 70 per share. The IPO comprised fresh issue of 18,60,000 equity shares. The promoter and promoter group shareholding will diluted to 72.89% from 100% pre-issue. The company intends to utilize the net proceeds for capital expenditure for office premises with furniture and industrial racks, working capital and general corporate purpose. Ahead of the IPO, Aptus Pharma on 22 September 2025, raised Rs 1 crore from anchor investors. The board allotted 1.44 lakh shares at Rs 70 each to 3 anchor investors. Aptus Pharma is engaged in the marketing and distribution of finished pharmaceutical formulations. The company operates through a contract manufacturing model and does not own any manufacturing facilities. It has contract manufacturing agreements with seven manufacturing units, including formal loan and license agreements with two units. The remaining production is managed through informal arrangements based on purchase orders. It offers a diverse range of pharmaceutical products across various therapeutic categories, including anti-infectives, gastrointestinal, antacids, anti-allergic and respiratory, nutritional supplements, pain management, neuro-psychiatric, cardiovascular, anti-diabetic, lipid-lowering, and general wellness. These products are available in multiple dosage forms such as tablets, capsules, softgels, syrups, suspensions, injections, ointments, creams, balms, drops, lotions, vials, powders, gels, and sachets. As of 31 May 2025, the company had total 70 employees. The company recorded revenue from operations of Rs 24.56 crore and net profit of Rs 3.10 crore for the year ended 31 March 2025. Powered by Capital Market - Live

The equity shares of Aptus Pharma (Scrip Code: 544529) are listed effective 30 September 2025 and admitted to dealings on the Exchange in the list of ''MT'' Group Securities. At 09:25 IST, the pre-open indicative price of the stock was at a premium of 14.57% to the offer price of Rs 70. Powered by Capital Market - Live